What is Phenylketonuria (PKU)?
Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism caused by mutations in the phenylalanine hydroxylase gene, resulting in complete absence or profound deficiency of the enzyme that converts phenylalanine (Phe) to tyrosine. 1
Clinical Manifestations
PKU causes dangerous accumulation of phenylalanine in blood and tissues. Without treatment, affected individuals develop:
- Severe intellectual disability and mental retardation
- Microcephaly (small head size)
- Delayed speech development
- Seizures
- Eczema
- Behavioral abnormalities 1
The neurotoxic effects of excessive phenylalanine directly damage the developing brain, with untreated patients showing blood Phe levels exceeding 20 mg/dL (1,210 μmol/L) 1.
Epidemiology
- Incidence: approximately 1 in 15,000 infants in the United States 1
- Higher rates in whites and Native Americans
- Lower rates in blacks, Hispanics, and Asians 1
- Parental consanguinity increases risk significantly (43.5% of PKU families report consanguinity) 2
The Critical Importance of Early Detection
Newborn screening programs, implemented universally in the United States since the 1960s, have been extraordinarily successful in preventing severe mental retardation. 1 Infants appear completely normal at birth, making screening essential 3. When diagnosed as newborns and appropriately treated, patients can expect normal health, development, and a normal life span. 1
What is an Inborn Error of Metabolism (IEM)?
Inborn errors of metabolism (IEMs) are a diverse group of monogenic (single-gene) disorders caused by enzyme deficiencies that result in either toxic accumulation of metabolic intermediates or shortage of essential end-products. 4
Key Characteristics of IEMs
IEMs represent inherited metabolic disorders where:
- A specific enzyme is deficient or absent due to genetic mutations
- Normal metabolic pathways are disrupted
- Toxic substances accumulate OR essential products are not produced
- Clinical manifestations vary widely depending on which metabolic pathway is affected 5, 4
PKU is one of the most common IEMs, with an incidence of 1:10,000 in the European population 5. It exemplifies how IEMs can be successfully managed when identified early through newborn screening programs 6.
PKU as a Prototype IEM
PKU represents a landmark in IEM management because it:
- Was the first IEM identified through general population screening in the 1960s 6
- Demonstrated that pre-symptomatic diagnosis and treatment could prevent severe neurological sequelae 6
- Set the stage for expansion of newborn screening to include additional metabolic disorders 6
- Showed that dietary intervention could effectively treat a genetic disorder 1
The success of PKU screening and treatment fundamentally altered the public health landscape for rare diseases and established the framework for managing other IEMs. 6